Significant Drop in Short Interest for Genenta Science S.p.A. (NASDAQ:GNTA)

Genenta Science S.p.A. (NASDAQ:GNTA) experienced a notable decline in short interest throughout February. By February 28th, the short interest had decreased to 1,500 shares, marking a 40.0% reduction from the 2,500 shares reported on February 13th. This decline reflects a minimal percentage, with currently 0.0% of the company's total shares being short sold. Given the average daily trading volume of 10,400 shares, the short-interest ratio stands at only 0.1 days.

Recent Institutional Investments in Genenta Science

In the fourth quarter, a hedge fund made a significant move by acquiring a new stake in Genenta Science. Citadel Advisors LLC has disclosed the purchase of 11,167 shares of Genenta Science S.p.A., which amounts to roughly $46,000. Following this acquisition, Citadel Advisors LLC holds about 0.06% of the company's total shares according to its latest filing with the Securities and Exchange Commission (SEC). Overall, institutional investors and hedge funds combined own approximately 15.13% of Genenta Science's stock.

Current Performance of Genenta Science Stock

On the trading day that just passed, GNTA shares fell by $0.11, leading to a closing price of $3.84. The trading volume recorded was 1,273 shares, considerably lower than the average volume of 8,263. The company's stock has a 50-day moving average of $4.07 and a 200-day moving average of $4.54. Over the past year, Genenta Science has seen its share price fluctuate between a low of $2.20 and a high of $7.28.

Overview of Genenta Science

Genenta Science S.p.A. is a biotechnology company that is currently in clinical development. The focus of the company is on creating hematopoietic stem cell gene therapies, specifically aimed at treating solid tumors in Italy. Their leading product candidate, Temferon, is presently undergoing Phase 1/2a clinical trials for the treatment of glioblastoma multiforme, particularly in patients with unmethylated MGMT gene promoter.

Considerations for Investors

Before deciding to invest in Genenta Science, potential investors may want to gather additional insights. MarketBeat has tracked evaluations from top analysts and discovered that while Genenta Science has received Buy ratings, there are also five stocks that analysts have identified as potentially more favorable investments. Evaluating these opportunities may provide a more well-rounded approach for investors seeking to allocate $1,000 or more.

Stocks, Investment, Performance